A post hoc analysis suggested that the improvement in cognition caused by 23 mg/d donepezil over 10 mg/d donepezil was not correlated with the age, weight, or sex of AD patients or the duration of treatment with previous low doses of donepezil
This prolongs the drug retention time in the nasal cavity, reduces the rapid elimination of the administered drug, and decreases the dose frequency
Long-term safety beyond 6 weeks remains completely unknown in humans
Thanks for highlighting Andrew
[DOI] [PMC free article] [PubMed] [Google Scholar] 14.Mansur R.B., Ahmed J., Cha D.S., Woldeyohannes H.O., Subramaniapillai M., Lovshin J., Lee J.G., Lee J.H., Brietzke E., Reininghaus E.Z., et al
W.et al (2024)